32

2

Logo

Synthebio

Company | France

Primary tabs

About your organization

Accelerator Application

The localized adiposity is a disease recognized by the WHO that affects 1.4 B people (3.3 B in 2030). Synthebio has developed, with CNRS experts, the Convergent Ultrasound technology that radically eliminates localized body fat excess (adiposity) and provides results never achieved until now: up to 5 cm. waistline reduction after one 20-minutes session. Synthebio has developed a non-invasive medical device, the Slimiser that also uses digital management of ultrasound, shape recognition based on based on IA, augmented reality guidance of the physician.
This medical device is being CE marked and should reach the market this year.
Dr. Kleinsinger runs Synthebio. He created and managed Optis - Eyegate Pharmaceuticals for 8 years, that went public and is listed on Nasdaq.
The body contouring market is huge (4 B€, 27 B€ in 2030), international and rapidly growing (19% per year). The goal is to develop a midsize company that could become a leader in the booming market of esthetic medicine.

News

Network (0)

There are no organizations in the network.

Recent activity

You are not connected

A certain number of contents are hidden from you and you do not benefit from the linking functionalities.

Log in or register to access to the entire contents and functionnalities. Subscription is quick and free.